EPA-Approved Antimicrobial Surface Coating Represents Breakthrough In The Control And Spread Of Infectious Diseases


NEW YORK, March 19, 2020 /PRNewswire/ -- Alistagen Corporation, a New York City-based biotechnology company, announced today that its Caliwel™ BNA, a non-toxic, natural mineral-based, antimicrobial, antiviral surface coating, which has been Environmental Protection Agency (EPA) approved since 2002, is effective against Influenza virus. Caliwel BNA has demonstrated through independent laboratory tests 99.9% effectiveness against more than 20 microbes that cause influenza, asthma, allergies, staph infection, polio, hepatitis, cholera and Legionnaires' disease. The coating has also been found to be effective against the Influenza virus and remains active against these microbes for up to 6 years. 

"This product represents a breakthrough in killing microbes responsible for a number of infectious diseases, including potentially SARS-CoV-2, the virus responsible for the COVID-19, pandemic," said Bryan Glynson, Chief Executive Officer of Alistagen. "The technology behind this product application represents a whole new category of infectious disease control. Through 20,000 completed Caliwel BNA applications, the products are well proven, and we are confident that Caliwel's use in preventing disease will offer untold benefits to people everywhere. Painting or otherwise coating an area with Caliwel BNA decontaminates the area. Caliwel BNA has both sufficient calcium hydroxide and moisture for the calcium hydroxide to kill any organisms on the surface being coated, whether the organisms are viruses, spores, mold, fungus or bacteria. Further, painting a surface with Caliwel BNA calcium hydroxide-based coating seals off any pathogenic organism on the painted surface in the unlikely event that it is not been entirely killed by the calcium hydroxide in the coating."

Caliwel works through its Bi-Neutralizing Agent (BNA) that harnesses the germ-killing power of calcium hydroxide (Ca[OH2]) in a new multipatented, microencapsulated formulation. Used for centuries to fight disease, the high alkalinity of Ca(OH)2 naturally kills microbes. The encapsulation process makes the Ca(OH)2 coating resistant to degradation for up to 6 years while maintaining its antimicrobial effectiveness.

"In light of the current pandemic and future outbreaks, every architectural setting at this point— from schools to hospitals to homes and offices—requires antiviral Caliwel BNA," said Mr. Glynson "Architectural surfaces play an imperative role in disease spread by serving as the major, if not the most imperative vector carrier for diseases."


Alistagen Caliwel BNA was invented in 2002 with the sole purpose of creating a non-invasive treatment that neutralizes fundamental disease vector carriers by utilizing already established architecture (ie, walls) as its own containment vector carrier. When treated with Caliwel BNA, established architecture provides years of safe and effective self-sanitizing for disease containment.

Most of the research and development of the Caliwel BNA technology was conducted by the Southwest Research Institute in San Antonio, Texas, among several other high-level testing facilities. Caliwel BNA kills most airborne microbes soon after they come in contact with a Caliwel-treated surface. Caliwel BNA coating minimizes the number of microbes in the environment, severely weakening their disease-causing powers. People exposed to a significantly reduced number of microbial spores are much less likely to become sick.

The technology was engineered for use in hospitals, schools and nursing homes. These institutions frequently harbor microbial infestations that are particularly threatening to children, the elderly and people with weakened immune systems. Hospital-acquired infections account for 2 million infections annually and some 90,000 deaths in the United States, according to the Centers for Disease Control and Prevention. Caliwel is also effective for killing mold and fungus on contact in homes and commercial buildings. Mold and fungus are increasingly cited as a contributing cause of "sick building syndrome" and of increased risk of asthma and allergies.

Conveniently, Caliwel BNA antiviral antimicrobial treatment also acts as a full substitute to a conventional architectural paint with an impeccable 12-year track record of public safety and efficacy proven through 20,000 successfully completed architectural projects (hospitals, nursing homes, schools, commercial buildings and private homes).  Caliwel BNA is applied in the same process as a conventional paint and offers a complete substitute for conventional interior architectural paint. Caliwel BNA is also available in selective designer colors.  Caliwel BNA combines function and design and offers unparalleled protection in every living environment.

Caliwel BNA is protected by seven domestic and international utility patents.  Caliwel BNA is U.S. EPA approved since 2002. Regulatory approvals: U.S. EPA, Reg. No. 73696-2, separate state of California EPA approval No. 73696, and separate HVAC EPA approval No. 73696.

The following selected list of viral species reflects the tests that were successfully conducted in course of U.S. EPA registration of Caliwel BNA (log reductions 8, 9 and 10): 

  • Influenza type A2  
  • Rhinovirus
  • Rotavirus
  • Adenovirus type 2
  • Respiratory syncytial
  • Hepatitis
  • Polio Virus Type I
  • Herpes Virus Type I
  • Parainfluenza Virus Type III

Alistagen Corporation conducted viral study, Study No. SWRI-96-01, Protocol No. SWRI062096, in compliance with the GLP regulations (Title 21 CFR 58) to determine the antiviral activity of Caliwel BNA (referred as Caliwel or BNA) antibiotic paint or coating. As a result, Polioviurs type 1, Herpesvirus hominis type 1 and parainfluenza virus type 3 were inactivated within minutes by exposure to test article Caliwel BNA Water base.

Caliwel BNA is available from leading retailers such The Home Depot and directly through Alistagen Corporation. Additional information and direct orders for Caliwel BNA can be obtained by visiting the company's Web site at www.caliwel.com or by calling (212) 317-0100.


Alistagen Corporation is a privately held biotechnology company founded in 2000. The company was established by CEO Bryan Glynson and President Alis Yeterian with the specific objective of developing noninvasive, therapeutic and preventive treatments for respiratory illnesses and infectious diseases that could be broadly applied to hospitals, nursing homes, residences and commercial structures which are susceptible to microbial infestation. Alistagen's mission is to globally market and/or license Caliwel BNA-based applications that reduce the spread of infectious disease and improve public health care.

Media Contact:
Allison Howell, Pascale Communications, LLC
(412) 228-1678
Email: allison@pascalecommunications.com

Tel. (212) 317-0100
Web: www.caliwel.com
Email: Information@Alistagen.com


Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/epa-approved-antimicrobial-surface-coating-represents-breakthrough-in-the-control-and-spread-of-infectious-diseases-301027074.html

SOURCE Alistagen Corporation


Back to news